Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.
Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales in excess of $2.6 billion in 2008.
For more information on Debiopharm Group, please visit: http://www.debiopharm.com.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signalling pathway drug technologies to seek to create new medicines for cancer indications. In expanding its drug development efforts in the field of cancer through its targeted cancer drug development platform, Curis is building upon its previous experiences in targeting signalling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at http://www.curis.com.
Curis Cautionary Statement: This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995, including without limitation the Company's statements regarding: the
expected timing and amount of payments to be received by Curis under the
license agreement with Debiopharm and the expected benefits of the agreement;
Debiopharm's plans to seek approval for the commencement of a phase I
clinical trial in Fall 2009; the estimated period in which Curis will have
cash to meet its operating requirements and its assumptions about factors
that may positively affect such period; expectations regarding the potential
benefits of CUDC- 305; its ability to further progres
|SOURCE Debiopharm Group|
Copyright©2009 PR Newswire.
All rights reserved